-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Odanacatib (ODN) is an oral selective cathepsin K (CatK) inhibitor for osteoporosis.
Compared with placebo, the proportion of periosteal double-label patients and bone formation index in ODN-treated patients increased over time
In summary, ODN treatment for 5 years did not reduce bone remodeling, and increased the proportion of patients with periosteal bone formation .
ODN treatment for 5 years did not reduce bone remodeling, and increased the proportion of patients with periosteal bone formation .
Source: Robert Recker, MD1, David Dempster, PhD2, Bente Langdah, Effects of Odanacatib on Bone Structure and Quality in Postmenopausal Women with Osteoporosis: 5-year Data from the Phase 3 Long-Term Odanacatib Fracture Trial (LOFT) and its Extension , J Bone Miner Res 2020 07;35(7)
Leave a message here